Breaking an absolute species barrier: transgenic mice expressing the mink PrP gene are susceptible to transmissible mink encephalopathy.

Transmissible mink encephalopathy (TME) is a rare disease of the North American mink, which has never been successfully transmitted to laboratory mice. We generated transgenic mice expressing the mink prion protein (PrP) and inoculated them with TME or the mouse-adapted scrapie strain 79A. TME infected mink PrP-transgenic mice on a murine PrP knockout background. The absolute species barrier between the infectious agent of TME and mice was therefore broken. Following TME and 79A infection of mice carrying both mink and murine PrP(C), only proteinase-resistant PrP homologous to the incoming agent was detectable. The presence of the murine PrP(C) prolonged the incubation time of TME substantially.

Preparation and substitution chemistry of [Bu4N]2[W6Cl8(p-OSO2C6H4CH3)6]. A useful precursor for pseudohalide, acetate, and organometallic complexes containing the [W6Cl8](4+) core.

The tosylate (p-toluenesulfonate) cluster [Bu4N]2[W6Cl8(p-OSO2C6H4CH3)6] (1) has been prepared and characterized by IR and NMR spectroscopy, elemental analysis, and an X-ray crystal structure. This cluster complex is shown to be a useful starting material for the preparation of pseudohalide clusters, [Bu4N]2[W6Cl8(NCQ)6] (Q = O (2), S (3), and Se (4)), in high yields. Cluster 1 also serves as a precursor to the new cluster compounds: [Bu4N]2[W6Cl8(O2CCH3)6] (5), [Bu4N]2[W6Cl8((mu-NC)Mn(CO)2(C5H5))6] (6), [W6Cl8((mu-NC)Ru(PPh3)2(C5H5))6][ p-OSO2C6H4CH3]4 (7), and [W6Cl8((mu-NC)Os(PPh3)2(C5H5))6][ p-OSO2C6H4CH3]4 (8). X-ray crystal structures are reported for 1, 4, and 5.

Molecular genetics of human prion diseases in Germany.

Human prion diseases may be acquired as infectious diseases, they may be inherited in an autosomal dominant fashion or occur sporadically. Mutations and polymorphisms in the sequence of the coding region of the prion protein gene (PRNP) have been established as an important factor in all of these three types of prion diseases. Therefore, a total of 578 patients with suspect prion diseases referred to the German Creutzfeldt-Jakob disease (CJD) surveillance unit over a period of 4.5 years have been examined for mutations and polymorphisms in the coding region of PRNP. We found 40 cases with a missense mutation previously reported as pathogenic. Amongst these, the aspartate to asparagine change at codon 178 (D178N) was the most common mutation. All of these cases carried the D178N mutation in coupling with methionine at codon 129, resulting in the typical fatal familial insomnia (FFI) genotype. Most cases with pathogenic mutations were not found in the group of clinically "probable" cases according to established clinical criteria, supporting the notion that inherited prion diseases often exhibit atypical features. Two novel missense mutations (T188R and P238S) and several silent polymorphisms were found, demonstrating the quality of our screening procedure based on a modified version of the single-stranded conformational polymorphism technique. In "definite" CJD cases with no pathogenic mutation, the patients clinically classified as "probable" were mostly homozygous for methionine at the common polymorphism at codon 129, whereas there was a marked over-representation of patients homozygous for valine amongst those clinically classified as "possible". This large study on suspect cases of human prion diseases in Germany clearly shows that PRNP genetics is essential for a comprehensive analysis of prion diseases.

Enzymatic synthesis, characterization, and metabolism of the coenzyme A ester of o-succinylbenzoic acid, an intermediate in menaquinone (vitamin K2) biosynthesis.

The enzymatic synthesis of the "active" o-succinylbenzoic acid is described and the factors controlling its formation are investigated. Tritium-labeled coenzyme A is incorporated into "active" o-succinylbenzoic acid, but label from [2-3H]ATP or [gamma-32P is not, indicating that the active compound is a coenzyme A thio ester(2). The compound is shown by two different methods to contain 1 mol only of coenzyme A per mol of o-succinylbenzoic acid. The o-succinylbenzoic and coenzyme A ester (2) is unstable at alkaline and neutral pH, but is fairly stable under acid conditions. The coenzyme A ester (2) is converted to 1,4-dihydroxy-2-naphthoic acid (3) by enzyme preparations from Mycobacterium phlei and Escherichia coli without any cofactor requirement.

Enzymic synthesis of o-succinylbenzoyl-CoA in cell-free extracts of anthraquinone producing Galium mollugo L. cell suspension cultures.

o-Succinylbenzoic acid (OSB) is an intermediate in the biosynthesis of shikimatederived anthraquinones. The cell free activation of o-succinylbenzoic acid in extracts of anthraquinone producing cells of Galium mollugo L. is demonstrated for the first time. This activation depends on the presence of ATP, coenzyme A and Mg(2+). The o-succinylbenzoic acid coenzyme A ester was identified by converting it to 1,4-dihydroxy-2-naphthoic acid by a bacterial enzyme, viz. naphthoatesynthase. It is thus demonstrated that the o-succinylbenzoic acid coenzyme A ester derived from bacteria and from Galium mollugo cells are identical.